BBK Worldwide Opens West Coast Office
BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide – Osaka in Japan, and adding to BBK’s existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
According to BBK Founding Principal Joan F. Bachenheimer, “Our West Coast clients operate in a hotbed of biopharmaceutical innovation. BBK’s on-site consultation better ensures their trials are primed for success with early recruitment strategies, technology, training, and tactical implementation support.”
On assignment from BBK’s global mobilization team, project and marketing experts will staff and augment the West Coast workforce, as needed, to respond directly to client and campaign needs. “Putting ‘feet on the street’ via a West Coast office means that we can better partner with clinical team leads as well as provide immediate, and if necessary, on-site enrollment coaching and training to study coordinators and site staff,” Bachenheimer added.
BBK Director of Strategic Development Andrew N. Sacher, Esq. commented, “We are finding with our presence in Osaka that real-time BBK availability in a region focused on biopharmaceutical innovation empowers clients to invest in the most advanced patient recruitment techniques. By opening the West Coast office, we anticipate spurring similar interest and commitment to enhancing clinical trial enrollment – particularly as the sheer number of biopharmaceutical studies being conducted continues to rise.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
